Xilio Therapeutics Inc expected to post a loss of 10 cents a share - Earnings Preview

Xilio Therapeutics Inc XLO is expected to show a rise in quarterly revenue when it reports results on August 6 (estimated) for the period ending June 30 2025

The Waltham Massachusetts-based company is expected to report a 214.0% increase in revenue to $7.4 million from $2.36 million a year ago, according to the estimate from one analyst, based on LSEG data.

​LSEG's mean analyst estimate for Xilio Therapeutics Inc is for a loss of 10 cents per share.

The one available analyst rating on the shares is "buy".

The mean earnings estimate of analysts was unchanged in the last three months. ​